Correspondence 0001193125-22-305870 from Benitec Biopharma Inc. (BNTC)
Benitec Biopharma Inc.
Date: Dec. 15, 2022 · CIK: 0001808898 · Accession: 0001193125-22-305870
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-268763
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-1004 Re: Benitec Biopharma Inc. Registration Statement on Form S-1 (File No. 333-268763)
Dear Mr. Howes,
Pursuant to Rule 461 of the Securities Act of 1933, as amended, Benitec Biopharma Inc. hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-268763), as amended, so that it may become effective at 4:15 p.m., Eastern Time on December 19, 2022, or as soon thereafter as practicable.
[Signature page follows]
Very truly yours,
BENITEC BIOPHARMA INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP BENITEC BIOPHARMA INC. 3940 Trust Way Hayward, California 94545 December 15, 2022 VIA EDGAR Tyler Howes United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-1004 Re: Benitec Biopharma Inc. Registration Statement on Form S-1 (File No. 333-268763) Dear Mr. Howes, Pursuant to Rule 461 of the Securities Act of 1933, as amended, Benitec Biopharma Inc. hereby requests acceleration of the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-268763), as amended, so that it may become effective at 4:15 p.m., Eastern Time on December 19, 2022, or as soon thereafter as practicable. [Signature page follows] Very truly yours, BENITEC BIOPHARMA INC. By: /s/ Dr. Jerel Banks Name: Dr. Jerel Banks Title: Chief Executive Officer [Signature Page to Acceleration Request]